This study found inappropriate DOAC prescriptions in 16.9% of hospitalized patients with AF, with underdosing being more common than overdosing. Moreover, this study identified determinants of DOAC under- and overdosing.
ESC 2021 In the ENVISAGE-TAVI AF trial, the effect of edoxaban on net adverse clinical events (NACE) was compared to VKAs in elderly patients with AF who underwent TAVI.
ESC 2021 The LOOP study showed that continuous heart rhythm monitoring using an implantable loop recorder and initiation of OAC if AF was detected, did not prevent stroke in patients at high risk compared to standard care.
ESC 2021 Non-inferiority was met for edoxaban when compared with VKA for net adverse clinical events (NACE) in patients with AF after TAVI, but major bleeding was higher in those receiving edoxaban.
ESC HF 2021 This analysis of the VICTORIA trial showed that the beneficial effects of vericiguat were unaffected by AF status at baseline.
ESC HF 2021 This subanalysis of the GALACTIC-HF trial showed that omecamtiv mecarbil treatment was less effective in HFrEF patients with baseline AF or atrial flutter (AFL), and this was prominent in digoxin treated patients with AF/AFL.
A randomized clinical trial compared the rate of detection of AF with use of an implantable loop recorder for 12 months vs. use of an external loop recorder for 30 days in patients with recent ischemic stroke without known AF.
This meta-analysis of five RCTs (REDUCE-IT, ASCEND, R&P, STRENGTH and OMEMI) showed that omega-3 fatty acids supplementation is associated with an increased risk of incident AF, compared to placebo.
This combined cohort study suggested that IL-6 and hs-CRP levels were associated with HF hospitalization and adverse outcomes in patients with AF. The risk for HF hospitalization increased with increasing inflammation scores of both inflammation markers.
The predictive performance of six risk scores for ischemic stroke in patients with AF and CKD were validated. The Modified CHADS2 score showed good performance for discrimination and calibration in all kidney function categories.
ACC 2021 Ablation-based rhythm control and rate control showed no statistically significant differences in the RAFT-AF trial for the primary outcome of all-cause mortality and HF events in patients with HF and high burden AF.
ACC 2021 Results from the HOLIDAY study suggest that just one alcoholic drink was associated with a 2-fold greater odds and two or more alcoholic drinks were associated with a 3.5-fold greater odds of a discrete AF episode occurring in the next four hours.